Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2LEBV and 2LXFS for Asthenia in EBV Infection
NCT04308278Phase 4Recruiting
- Sponsor
- Labo'Life
- Start
- Jan 2021
- Primary completion
- Aug 2028
- Modality
- DNA Therapeutics, Cytokines & Interferons, Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of 2LEBV, 2LXFS in Epstein-Barr virus infection, asthenia, sponsored by Labo'Life. Started Jan 2021; status: recruiting.
02
Drugs
2LEBV2LXFS
03
Conditions
Epstein-Barr virus infectionasthenia
Beyond the preview
Go deeper on NCT04308278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308278.